Hengrui Pharma (01276) has announced that its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd., has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA) for the SHR-1179 injection, paving the way for the initiation of clinical trials in the near future.

The SHR-1179 injection, developed in-house by the company, is a Class 1 therapeutic biological product intended for weight management indications. Notably, no drugs targeting the same pathway have yet been approved for marketing either domestically or internationally.

As of the date of this announcement, the cumulative research and development investment in the SHR-1179 injection project amounts to approximately RMB 24.2 million (unaudited).